恩替卡韦与拉米夫定治疗慢性乙型肝炎初治患者的疗效对比  

作　　者：邱邦东[1] 陈超[1] 叶清琦 姚玲[1] 王成军[1] 崔文星[1] 

机构地区：[1]四川省宜宾市第二人民医院感染一科,四川宜宾644000

出　　处：《中国药业》2015年第B12期38-39,共2页China Pharmaceuticals

摘　　要：目的对比观察恩替卡韦（国产）、与拉夫米定（进口）对慢性乙型肝炎（CHB）初治患者的临床疗效。方法随机将65例首次服用抗病毒药物治疗的慢性乙肝患者分为观察组33例、对照组32例，分别给予恩替卡韦0．5mg／d、拉夫米定100mg／d口服。结果用药半年后观察组完全应答率为51．52％，明显高于对照组的21．88％（p=6．13，P〈0．05）；观察组丙氨酸氨基转移酶（ALT）复常率、乙型肝炎病毒DNA（HBVDNA）转阴率均高于对照组（P〈0．05），但HBeAg转阴率无明显差异（P〉0．05）。结论与拉米夫定（进口）相比，恩替卡韦（国产）更能有效抑制慢性乙肝患者HBVDNA复制，可用于慢性乙肝长期治疗。Objective To contract clinical efficacy of Entecavir and Lamivudine on patients with chronic viral hepatitis B （CHB） for the first time.Methods 65 patients with CHB treated for the first time were divided into the observation group （n=33） and the control group（n=32）,respectively given by Entecavir （0.5mg/d） and Lamivudine （lOOmg/d）.Results After 6 months treatment, the total response rate in the observation group was 51.52%,higher than that of the control group（21.88%;χ2=6.13,P〈0.05）;the recover rate of ALT and the turn-over-negative rate of HBV DNA were both higher than them of the control group （P〈0.05）,but there was no difference in the turn-over-negative rate of HBeAg （P〉 0.05 ）.Conclusion Compared with the Lamivudine, Entecavir has stronger suppression to the copy of HBV DNA,and can be used for long-term treatment of CHB.

关 键 词：慢性乙型肝炎 恩替卡韦 拉夫米定 

分 类 号：R512.62[医药卫生—内科学]